Investigational therapies for metastatic thyroid carcinoma Journal Article


Authors: Tuttle, R. M.; Leboeuf, R.
Article Title: Investigational therapies for metastatic thyroid carcinoma
Abstract: Although traditional chemotherapy has yielded disappointing results in the therapy of progressive metastatic thyroid cancer, the recent development of a wide range of novel therapies targeting critical steps in the pathogenesis of thyroid cancer has led to a renewed interest in thyroid cancer clinical trials. This review provides an overview of the pathogenesis of thyroid cancer with particular emphasis on specific molecular targets that can be modulated with these novel agents. The article reviews the results for the small number of thyroid cancer patients included in published therapeutic trials and critically examines patient selection criteria for inclusion in clinical trials. Given the dramatic increase in availability of thyroid cancer clinical trials, all patients with radioactive iodine-refractory, progressive metastatic thyroid cancer should be considered for inclusion in a novel therapy trial. © Journal of the National Comprehensive Cancer Network.
Keywords: signal transduction; vasculotropin; gene mutation; thalidomide; review; carcinoma, squamous cell; sorafenib; angiogenesis inhibitor; bevacizumab; sunitinib; patient selection; antineoplastic agents; unindexed drug; metastasis; bortezomib; mitogen activated protein kinase inhibitor; epidermal growth factor receptor; carcinoma, papillary; antineoplastic activity; cetuximab; tyrosine kinase inhibitors; monoclonal antibody; epigenetics; celecoxib; mammalian target of rapamycin; gefitinib; combretastatin a4; vandetanib; vatalanib; vorinostat; 5 aza 2' deoxycytidine; thyroid cancer; thyroid carcinoma; thyroid neoplasms; isotretinoin; trastuzumab; rosiglitazone; b raf kinase; rapamycin; clinical trials; azacitidine; valproic acid; scatter factor receptor; carcinoma, medullary; geldanamycin; cancer gene therapy; 2 (2 amino 3 methoxyphenyl)chromone; novel therapy; therapies, investigational
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 5
Issue: 6
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2007-07-01
Start Page: 641
End Page: 646
Language: English
PUBMED: 17623615
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 10" - "Export Date: 17 November 2011" - "Source: Scopus"
Citation Impact
MSK Authors
  1. Robert M Tuttle
    483 Tuttle